Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4LWV

The 2.3A Crystal Structure of Humanized Xenopus MDM2 with RO5545353

Summary for 4LWV
Entry DOI10.2210/pdb4lwv/pdb
Related4LWT 4LWU
DescriptorE3 ubiquitin-protein ligase Mdm2, (2S,3R,4R,5R)-N-(4-carbamoyl-2-methoxyphenyl)-2'-chloro-4-(3-chloro-2-fluorophenyl)-2-(2,2-dimethylpropyl)-5'-oxo-4',5'-dihydrospiro[pyrrolidine-3,6'-thieno[3,2-b]pyrrole]-5-carboxamide, SULFATE ION, ... (4 entities in total)
Functional Keywordsmdm2, e3 ubiquitin ligase, p53, nucleus, ligase-ligase inhibitor complex, ligase/ligase inhibitor
Biological sourceXenopus laevis (clawed frog,common platanna,platanna)
Cellular locationNucleus, nucleoplasm (By similarity): P56273
Total number of polymer chains3
Total formula weight31641.05
Authors
Graves, B.J.,Lukacs, C.,Janson, C.A. (deposition date: 2013-07-28, release date: 2014-07-02, Last modification date: 2024-02-28)
Primary citationZhang, Z.,Chu, X.J.,Liu, J.J.,Ding, Q.,Zhang, J.,Bartkovitz, D.,Jiang, N.,Karnachi, P.,So, S.S.,Tovar, C.,Filipovic, Z.M.,Higgins, B.,Glenn, K.,Packman, K.,Vassilev, L.,Graves, B.
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.
ACS MED.CHEM.LETT., 5:124-127, 2014
Cited by
PubMed Abstract: The development of small-molecule MDM2 inhibitors to restore dysfunctional p53 activities represents a novel approach for cancer treatment. In a previous communication, the efforts leading to the identification of a non-imidazoline MDM2 inhibitor, RG7388, was disclosed and revealed the desirable in vitro and in vivo pharmacological properties that this class of pyrrolidine-based inhibitors possesses. Given this richness and the critical need for a wide variety of chemical structures to ensure success in the clinic, research was expanded to evaluate additional derivatives. Here we report two new potent, selective, and orally active p53-MDM2 antagonists, RO5353 and RO2468, as follow-ups with promising potential for clinical development.
PubMed: 24900784
DOI: 10.1021/ml400359z
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.32 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon